Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea

Loading news article.

Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea | WAPE

Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea

Article summary

Related companies

Comments —